Charles Schwab
ESPR

Charles Schwab’s Esperion Therapeutics ESPR Stock Holding History

Charles Schwab’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Buy
742,245
+71,960
+11% +$201K ﹤0.01% 2743
2026
Q1 		$1.84M Sell
670,285
-45,041
-6% -$143K ﹤0.01% 2740
2025
Q4 		$2.65M Buy
715,326
+128,902
+22% +$417K ﹤0.01% 2680
2025
Q3 		$1.55M Sell
586,424
-30,715
-5% -$59.4K ﹤0.01% 2813
2025
Q2 		$608K Buy
617,139
+62,923
+11% +$63K ﹤0.01% 3073
2025
Q1 		$798K Hold
554,216
– – ﹤0.01% 2917
2024
Q4 		$1.22M Sell
554,216
-698
-0.1% -$1.63K ﹤0.01% 2837
2024
Q3 		$916K Hold
554,914
– – ﹤0.01% 2944
2024
Q2 		$1.23M Buy
554,914
+496,923
+857% +$1.17M ﹤0.01% 2849
2024
Q1 		$155K Hold
57,991
– – ﹤0.01% 3265
2023
Q4 		$173K Hold
57,991
– – ﹤0.01% 3291
2023
Q3 		$56.8K Buy
+57,991
New +$83.9K ﹤0.01% 3397
2023
Q2 		– Sell
-199,811
Closed -$318K – 3631
2023
Q1 		$318K Buy
199,811
+2,859
+1% +$14.8K ﹤0.01% 3076
2022
Q4 		$1.23M Buy
196,952
+27,126
+16% +$194K ﹤0.01% 2714
2022
Q3 		$1.14M Buy
169,826
+8,011
+5% +$55K ﹤0.01% 2750
2022
Q2 		$1.03M Buy
161,815
+9,606
+6% +$54.5K ﹤0.01% 2783
2022
Q1 		$707K Buy
152,209
+71,549
+89% +$307K ﹤0.01% 2987
2021
Q4 		$404K Buy
80,660
+12,577
+18% +$101K ﹤0.01% 3218
2021
Q3 		$821K Sell
68,083
-122,414
-64% -$1.78M ﹤0.01% 2947
2021
Q2 		$4.03M Buy
190,497
+4,315
+2% +$104K ﹤0.01% 2449
2021
Q1 		$5.22M Buy
186,182
+4,894
+3% +$144K ﹤0.01% 2282
2020
Q4 		$4.71M Buy
181,288
+3,263
+2% +$97.7K ﹤0.01% 2246
2020
Q3 		$6.62M Buy
178,025
+8,823
+5% +$349K ﹤0.01% 1933
2020
Q2 		$8.68M Sell
169,202
-14,529
-8% -$608K ﹤0.01% 1728
2020
Q1 		$5.79M Sell
183,731
-38,221
-17% -$2.02M ﹤0.01% 1759
2019
Q4 		$13.2M Sell
221,952
-18,742
-8% -$843K 0.01% 1494
2019
Q3 		$8.82M Buy
240,694
+52,309
+28% +$2.07M 0.01% 1673
2019
Q2 		$8.76M Buy
188,385
+51,343
+37% +$2.41M 0.01% 1681
2019
Q1 		$5.5M Buy
137,042
+5,069
+4% +$227K ﹤0.01% 1941
2018
Q4 		$6.07M Sell
131,973
-2,563
-2% -$123K ﹤0.01% 1791
2018
Q3 		$5.97M Buy
134,536
+23,147
+21% +$1.06M ﹤0.01% 1954
2018
Q2 		$4.37M Buy
111,389
+15,947
+17% +$806K ﹤0.01% 2070
2018
Q1 		$6.9M Buy
95,442
+4,471
+5% +$328K 0.01% 1759
2017
Q4 		$5.99M Sell
90,971
-872
-0.9% -$46.9K ﹤0.01% 1826
2017
Q3 		$4.6M Buy
91,843
+23,568
+35% +$1.14M ﹤0.01% 1922
2017
Q2 		$3.16M Buy
68,275
+13,146
+24% +$483K ﹤0.01% 2044
2017
Q1 		$1.95M Buy
55,129
+9,478
+21% +$217K ﹤0.01% 2206
2016
Q4 		$572K Buy
45,651
+21,787
+91% +$259K ﹤0.01% 2606
2016
Q3 		$331K Sell
23,864
-17,580
-42% -$199K ﹤0.01% 2753
2016
Q2 		$410K Sell
41,444
-5,106
-11% -$84.6K ﹤0.01% 2664
2016
Q1 		$788K Buy
46,550
+1,001
+2% +$16.1K ﹤0.01% 2417
2015
Q4 		$1.01M Buy
45,549
+1,413
+3% +$35.6K ﹤0.01% 2382
2015
Q3 		$1.04M Buy
44,136
+21,666
+96% +$1.36M ﹤0.01% 2368
2015
Q2 		$1.84M Buy
22,470
+13,270
+144% +$1.3M ﹤0.01% 2144
2015
Q1 		$852K Buy
9,200
+2,100
+30% +$136K ﹤0.01% 2435
2014
Q4 		$288K Buy
+7,100
New +$217K ﹤0.01% 2856

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Charles Schwab's ESPR Position: Q2 2026 in Review

Charles Schwab increased its Esperion Therapeutics (ESPR) stake by 11% in Q2 2026, buying an estimated $201K and bringing the position to 742,245 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2743.

Charles Schwab first reported a position in ESPR in Q4 2014 and has held it in 46 quarters since. The position peaked at $13.2M in Q4 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Charles Schwab held 742,245 shares of Esperion Therapeutics worth $2.35M as of Q2 2026.
  • Charles Schwab bought 71,960 Esperion Therapeutics shares in Q2 2026, an estimated $201K.
  • Esperion Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2743 holding.
  • Charles Schwab first reported a position in Esperion Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • Charles Schwab's Esperion Therapeutics position peaked at $13.2M in Q4 2019.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.